Skip to main content
Erschienen in: Annals of Hematology 6/2014

01.06.2014 | Original Article

Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards

verfasst von: Lika’a Fasih Y. Al-Kzayer, Le Thanh N. Uyen, Mazin Faisal Al-Jadiry, Salma Abbas Al-Hadad, Safaa A. Faraj Al-Badri, Hasanein Habeeb Ghali, Najiha Ahmed Ameen, Tingting Liu, Kazuyuki Matsuda, Jaafar M. H. Abdulkadhim, Tariq Abadi Al-Shujairi, Zead Ismael I. K. Matti, Janan Ghalib Hasan, Hussam M. Salih Al-Abdullah, Mouroge H. Al-Ani, Paiman Ali I. Saber, Hisham Maree Khalil, Toshi Inoshita, Minoru Kamata, Kenichi Koike, Kazuo Sakashita

Erschienen in: Annals of Hematology | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

The lack of molecular diagnosis in the field of cancer in Iraq has motivated us to perform a genetic analysis of pediatric acute myelogenous leukemia (AML), including class I and II aberrations. Peripheral blood or bone marrow cells were collected from 134 AML children aged ≤15 years. Flinders Technology Associates (FTA) filter paper cards were used to transfer dried blood samples from five Iraqi hospitals to Japan. DNA sequencing was performed to identify class I mutations. Nested RT-PCR was used to detect class II aberrations, except that MLL rearrangement was detected according to long distance inverse-PCR. NPM1 and FMS-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutations were analyzed by GeneScan using DNA template. Among 134 Iraqi pediatric AML samples, the most prevalent FAB subtype was M2 (33.6 %) followed by M3 (17.9 %). Class I mutations: 20 (14.9 %), 8 (6.0 %), and 8 (6.0 %) patients had FLT3-ITD, FLT3-TKD, and KIT mutations, respectively. Class II mutations: 24 (17.9 %), 19 (14.2 %), and 9 (6.7 %) children had PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 transcripts, respectively. MLL rearrangements were detected in 25 (18.7 %) patients. NPM1 mutation was detected in seven (5.2 %) cases. Collectively, approximately 30 % of AML children were proved to carry favorable prognostic genetic abnormalities, whereas approximately 10 % had high FLT3-ITD allelic burden and needed a special treatment plan including allogeneic hematopoietic stem cell transplantation. Acute promyelocytic leukemia (APL) was frequent among Iraqi pediatric AML. It is likely that molecular diagnosis using FTA cards in underdeveloped countries could guide doctors towards an appropriate treatment strategy.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, Al-Saeed RM, Al-Badr SF, Ghali HH (2011) Reality of pediatric cancer in Iraq. J Pediatr Hematol Oncol 33(Suppl 2):S154–S156PubMedCrossRef Al-Hadad SA, Al-Jadiry MF, Al-Darraji AF, Al-Saeed RM, Al-Badr SF, Ghali HH (2011) Reality of pediatric cancer in Iraq. J Pediatr Hematol Oncol 33(Suppl 2):S154–S156PubMedCrossRef
2.
Zurück zum Zitat Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532–1542PubMedCrossRef Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532–1542PubMedCrossRef
3.
Zurück zum Zitat Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 400–411 Haferlach T (2008) Molecular genetic pathways as therapeutic targets in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 400–411
4.
Zurück zum Zitat Balgobind BV, Hollink IH, Arentsen-Peters ST et al (2011) Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 96(10):1478–1487PubMedCentralPubMedCrossRef Balgobind BV, Hollink IH, Arentsen-Peters ST et al (2011) Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica 96(10):1478–1487PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Falini B, Mecucci C, Tiacci E et al (2005) GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266PubMedCrossRef Falini B, Mecucci C, Tiacci E et al (2005) GIMEMA Acute Leukemia Working Party. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352(3):254–266PubMedCrossRef
6.
Zurück zum Zitat Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 27(4):171–181PubMedCentralPubMedCrossRef Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 27(4):171–181PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat Meshinchi S, Woods WG, Stirewalt DL et al (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97(1):89–94PubMedCrossRef Meshinchi S, Woods WG, Stirewalt DL et al (2001) Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97(1):89–94PubMedCrossRef
8.
Zurück zum Zitat Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98(6):1752–1759PubMedCrossRef Kottaridis PD, Gale RE, Frew ME et al (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98(6):1752–1759PubMedCrossRef
9.
Zurück zum Zitat Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335PubMedCrossRef Thiede C, Steudel C, Mohr B et al (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99(12):4326–4335PubMedCrossRef
10.
Zurück zum Zitat Zwaan CM, Meshinchi S, Radich JP et al (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102(7):2387–2394PubMedCrossRef Zwaan CM, Meshinchi S, Radich JP et al (2003) FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 102(7):2387–2394PubMedCrossRef
11.
12.
Zurück zum Zitat Whitman SP, Ruppert AS, Radmacher MD et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111(3):1552–1559PubMedCentralPubMed Whitman SP, Ruppert AS, Radmacher MD et al (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111(3):1552–1559PubMedCentralPubMed
13.
Zurück zum Zitat Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):776–784 Gale RE, Green C, Allen C et al (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111(5):776–784
14.
Zurück zum Zitat Cairoli R, Beghini A, Grillo G et al (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107(9):3463–3468PubMedCrossRef Cairoli R, Beghini A, Grillo G et al (2006) Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 107(9):3463–3468PubMedCrossRef
15.
Zurück zum Zitat Boissel N, Leroy H, Brethon B et al (2006) Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20(6):965–970PubMedCrossRef Boissel N, Leroy H, Brethon B et al (2006) Acute Leukemia French Association (ALFA); Leucémies Aiguës Myéloblastiques de l’Enfant (LAME) Cooperative Groups. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 20(6):965–970PubMedCrossRef
16.
Zurück zum Zitat Paschka P, Marcucci G, Ruppert AS et al (2006) Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24(24):3904–3911PubMedCrossRef Paschka P, Marcucci G, Ruppert AS et al (2006) Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 24(24):3904–3911PubMedCrossRef
17.
Zurück zum Zitat Goemans BF, Zwaan CM, Miller M et al (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19(9):1536–1542PubMedCrossRef Goemans BF, Zwaan CM, Miller M et al (2005) Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia 19(9):1536–1542PubMedCrossRef
18.
Zurück zum Zitat Pollard JA, Alonzo TA, Gerbing RB et al (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12):2372–2379PubMedCentralPubMedCrossRef Pollard JA, Alonzo TA, Gerbing RB et al (2010) Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 115(12):2372–2379PubMedCentralPubMedCrossRef
19.
Zurück zum Zitat Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S (2005) Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 130(2):196–202PubMedCrossRef Kuchenbauer F, Schoch C, Kern W, Hiddemann W, Haferlach T, Schnittger S (2005) Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia. Br J Haematol 130(2):196–202PubMedCrossRef
20.
Zurück zum Zitat Balgobind BV, Raimondi SC, Harbott J et al (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114(12):2489–2496PubMedCentralPubMedCrossRef Balgobind BV, Raimondi SC, Harbott J et al (2009) Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 114(12):2489–2496PubMedCentralPubMedCrossRef
21.
Zurück zum Zitat Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011–4020PubMedCrossRef Thiede C, Koch S, Creutzig E et al (2006) Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107(10):4011–4020PubMedCrossRef
22.
Zurück zum Zitat Döhner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740–3746PubMedCrossRef Döhner K, Schlenk RF, Habdank M et al (2005) Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 106(12):3740–3746PubMedCrossRef
23.
Zurück zum Zitat Al-Kzayer LF, Sakashita K, Matsuda K et al (2012) Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards. Pediatr Blood Cancer 59(3):461–467PubMedCrossRef Al-Kzayer LF, Sakashita K, Matsuda K et al (2012) Genetic evaluation of childhood acute lymphoblastic leukemia in Iraq using FTA cards. Pediatr Blood Cancer 59(3):461–467PubMedCrossRef
24.
Zurück zum Zitat Testi AM, Al-Hadad SA, Al-Jadiry MF, Moleti ML, Mandelli F, Foà R (2006) Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq. Haematologica 91(4):509–512PubMed Testi AM, Al-Hadad SA, Al-Jadiry MF, Moleti ML, Mandelli F, Foà R (2006) Impact of international collaboration on the prognosis of childhood acute promyelocytic leukemia in Iraq. Haematologica 91(4):509–512PubMed
25.
Zurück zum Zitat Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG (1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94(1):12–22PubMed Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG (1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94(1):12–22PubMed
26.
Zurück zum Zitat Meyer C, Schneider B, Reichel M et al (2005) Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 102(2):449–454PubMedCentralPubMedCrossRef Meyer C, Schneider B, Reichel M et al (2005) Diagnostic tool for the identification of MLL rearrangements including unknown partner genes. Proc Natl Acad Sci U S A 102(2):449–454PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Meyer C, Marschalek R (2009) LDI-PCR: identification of known and unknown gene fusions of the human MLL gene. Methods Mol Biol 538:71–83PubMedCrossRef Meyer C, Marschalek R (2009) LDI-PCR: identification of known and unknown gene fusions of the human MLL gene. Methods Mol Biol 538:71–83PubMedCrossRef
28.
Zurück zum Zitat Creutzig U, van den Heuvel-Eibrink MM, Gibson B et al (2012) On behalf of the AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120(16):3187–3205PubMedCrossRef Creutzig U, van den Heuvel-Eibrink MM, Gibson B et al (2012) On behalf of the AML Committee of the International BFM Study Group. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 120(16):3187–3205PubMedCrossRef
29.
Zurück zum Zitat Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T (2011) Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Haematologica 96(12):1799–1807PubMedCentralPubMedCrossRef Schnittger S, Bacher U, Haferlach C, Kern W, Alpermann T, Haferlach T (2011) Clinical impact of FLT3 mutation load in acute promyelocytic leukemia with t(15;17)/PML-RARA. Haematologica 96(12):1799–1807PubMedCentralPubMedCrossRef
30.
Zurück zum Zitat Gale RE, Hills R, Pizzey AR et al (2005) NCRI Adult Leukaemia Working Party. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106(12):3768–3776PubMedCrossRef Gale RE, Hills R, Pizzey AR et al (2005) NCRI Adult Leukaemia Working Party. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 106(12):3768–3776PubMedCrossRef
31.
Zurück zum Zitat von Neuhoff C, Reinhardt D, Sander A et al (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 28(16):2682–2689CrossRef von Neuhoff C, Reinhardt D, Sander A et al (2010) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 28(16):2682–2689CrossRef
32.
Zurück zum Zitat Pui CH, Carroll WL, Meshinchi S, Arceci RJ (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29(5):551–565PubMedCentralPubMedCrossRef Pui CH, Carroll WL, Meshinchi S, Arceci RJ (2011) Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 29(5):551–565PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Raimondi SC, Chang MN, Ravindranath Y et al (1999) Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 94(11):3707–3716PubMed Raimondi SC, Chang MN, Ravindranath Y et al (1999) Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 8821. Blood 94(11):3707–3716PubMed
34.
Zurück zum Zitat Ribeiro RC, Rego E (2006) Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program:162–168 Ribeiro RC, Rego E (2006) Management of APL in developing countries: epidemiology, challenges and opportunities for international collaboration. Hematology Am Soc Hematol Educ Program:162–168
35.
Zurück zum Zitat Thomas X (2000) Is there any genetic susceptibility to acute promyelocytic leukemia? Leukemia 14(12):2324–2326PubMedCrossRef Thomas X (2000) Is there any genetic susceptibility to acute promyelocytic leukemia? Leukemia 14(12):2324–2326PubMedCrossRef
36.
Zurück zum Zitat Frascella E, Rondelli R, Pigazzi M et al (2004) Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia 18(8):1427–1429PubMedCrossRef Frascella E, Rondelli R, Pigazzi M et al (2004) Clinical features of childhood acute myeloid leukaemia with specific gene rearrangements. Leukemia 18(8):1427–1429PubMedCrossRef
37.
Zurück zum Zitat Wells RJ, Arthur DC, Srivastava A et al (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children’s Cancer Group Study 213. Leukemia 16(4):601–607PubMedCrossRef Wells RJ, Arthur DC, Srivastava A et al (2002) Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children’s Cancer Group Study 213. Leukemia 16(4):601–607PubMedCrossRef
Metadaten
Titel
Analysis of class I and II aberrations in Iraqi childhood acute myeloid leukemia using filter paper cards
verfasst von
Lika’a Fasih Y. Al-Kzayer
Le Thanh N. Uyen
Mazin Faisal Al-Jadiry
Salma Abbas Al-Hadad
Safaa A. Faraj Al-Badri
Hasanein Habeeb Ghali
Najiha Ahmed Ameen
Tingting Liu
Kazuyuki Matsuda
Jaafar M. H. Abdulkadhim
Tariq Abadi Al-Shujairi
Zead Ismael I. K. Matti
Janan Ghalib Hasan
Hussam M. Salih Al-Abdullah
Mouroge H. Al-Ani
Paiman Ali I. Saber
Hisham Maree Khalil
Toshi Inoshita
Minoru Kamata
Kenichi Koike
Kazuo Sakashita
Publikationsdatum
01.06.2014
Verlag
Springer Berlin Heidelberg
Erschienen in
Annals of Hematology / Ausgabe 6/2014
Print ISSN: 0939-5555
Elektronische ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2007-2

Weitere Artikel der Ausgabe 6/2014

Annals of Hematology 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.